Javier Castillo-Olivares

Dr. Javier Castillo-Olivares

University of Cambridge, Cambridge CB3 0ES, UK
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2004 in Veterinary Research
Verified
Journal Article
Open access
PDF file
JCJavier Castillo-Olivares
Javier Castillo-Olivares
JWJames Wood
James Wood
West Nile virus (WNV) is a flavivirus closely related to Japanese encephalitis and St. Louis encephalitis viruses that is primarily maintained in nature by transmission cycles between mosquitoes and birds. Occasionally, WNV infects and causes disease in other vertebrates, including humans and horses. West Nile virus has re-emerged as an important pathogen as several recent outbreaks of encephalomyelitis have been reported from different parts of Europe in addition to the large epidemic that has swept across North America. This review summarises the main features of WNV infection in the horse, with reference to complementary information from other species, highlighting the most recent scientific findings and identifying areas that require further research.

26 January 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJavier Castillo-Olivares
Javier Castillo-Olivares
ECEva Calvo-Pinilla
Eva Calvo-Pinilla
ICIsabel Casanova
Isabel Casanova
KBKatarzyna Bachanek-Bankowska
Katarzyna Bachanek-Bankowska
RCRachael Chiam
Rachael Chiam
Peter MertensPeter Mertens
Peter Mertens
African horse sickness (AHS) is a lethal viral disease of equids, which is transmitted by Culicoides midges that become infected after biting a viraemic host. The use of live attenuated vaccines has been vital for the control of this disease in endemic regions. However, there are safety concerns over their use in non-endemic countries. Research efforts over the last two decades have therefore focused on developing alternative vaccines based on recombinant baculovirus or live viral vectors expressing structural components of the AHS virion. However, ethical and financial considerations, relating to the use of infected horses in high biosecurity installations, have made progress very slow. We have therefore assessed the potential of an experimental mouse-model for AHSV infection for vaccine and immunology research. We initially characterised AHSV infection in this model, then tested the protective efficacy of a recombinant vaccine based on modified vaccinia Ankara expressing AHS-4 VP2 (MVA-VP2).

12 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TJTamara Kusay Jabbar
Tamara Kusay Jabbar
ECEva Calvo-Pinilla
Eva Calvo-Pinilla
FMFrancisco Mateos
Francisco Mateos
SGSimon Gubbins
Simon Gubbins
ABAbdelghani Bin-Tarif
Abdelghani Bin-Tarif
JCJavier Castillo-Olivares
Javier Castillo-Olivares
The protective efficacy of recombinant vaccines expressing serotype 8 bluetongue virus (BTV-8) capsid proteins was tested in a mouse model. The recombinant vaccines comprised plasmid DNA or Modified Vaccinia Ankara viruses encoding BTV VP2, VP5 or VP7 proteins. These constructs were administered alone or in combination using either a homologous prime boost vaccination regime (rMVA/rMVA) or a heterologous vaccination regime (DNA/rMVA). The DNA/rMVA or rMVA/rMVA prime-boost were administered at a three week interval and all of the animals that received VP2 generated neutralising antibodies. The vaccinated and non-vaccinated-control mice were subsequently challenged with a lethal dose of BTV-8. Mice vaccinated with VP7 alone were not protected. However, mice vaccinated with DNA/rMVA or rMVA/rMVA expressing VP2, VP5 and VP7 or VP2 alone were all protected.

1 March 2014 in Virus Research
Verified
Journal Article
Open access
ECEva Calvo-Pinilla
Eva Calvo-Pinilla
JCJavier Castillo-Olivares
Javier Castillo-Olivares
TJTamara Jabbar
Tamara Jabbar
JOJavier Ortego
Javier Ortego
FPFrancisco de la Poza
Francisco de la Poza
AMAlejandro Marin-Lopez
Alejandro Marin-Lopez
Bluetongue (BT) is a hemorrhagic disease of ruminants caused by bluetongue virus (BTV), the prototype member of the genus Orbivirus within the family Reoviridae and is transmitted via biting midges of the genus Culicoides. BTV can be found on all continents except Antarctica, and up to 26 immunologically distinct BTV serotypes have been identified. Live attenuated and inactivated BTV vaccines have been used over the years with different degrees of success. The multiple outbreaks of BTV in Mediterranean Europe in the last two decades and the incursion of BTV-8 in Northern Europe in 2008 has re-stimulated the interest to develop improved vaccination strategies against BTV. In particular, safer, cross-reactive, more efficacious vaccines with differential diagnostic capability have been pursued by multiple BTV research groups and vaccine manufacturers. A wide variety of recombinant BTV vaccine prototypes have been investigated, ranging from baculovirus-expressed sub-unit vaccines to the use of live viral vectors. This article gives a brief overview of all these modern approaches to develop vaccines against BTV including some recent unpublished data.

1 June 2014 in Vaccine
Verified
Journal Article
Open access
BABerta Alberca
Berta Alberca
KBKatarzyna Bachanek-Bankowska
Katarzyna Bachanek-Bankowska
MCMarta Cabana
Marta Cabana
ECEva Calvo-Pinilla
Eva Calvo-Pinilla
EVElisenda Viaplana
Elisenda Viaplana
JCJavier Castillo-Olivares
Javier Castillo-Olivares
African horse sickness virus (AHSV) is an arthropod-borne pathogen that infects all species of equidae and causes high mortality in horses. Previously, a recombinant modified vaccinia Ankara (MVA) virus expressing the protein VP2 of AHSV serotype 4 was shown to induce virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR -/-) against virulent AHSV challenge. This study builds on the previous work, examining the protective efficacy of MVA-VP2 vaccination in the natural host of AHSV infection. A study group of 4 horses was vaccinated twice with a recombinant MVA virus expressing the major capsid protein (VP2) of AHSV serotype 9. Vaccinated animals and a control group of unvaccinated horses were then challenged with a virulent strain of AHSV-9. The vaccinated animals were completely protected against clinical disease and also against viraemia as measured by standard end-point dilution assays. In contrast, all control horses presented viraemia after challenge and succumbed to the infection. These results demonstrate the potential of recombinant MVA viruses expressing the outer capsid VP2 of AHSV as a protective vaccine against AHSV infection in the field.

2 October 2020 in Equine Veterinary Journal
Verified
Journal Article
Open access
PDF file
JCJavier Castillo-Olivares
Javier Castillo-Olivares
Click on the article title to read more.